C Diff Drug Development

Seres Therapeutics shared phase 3 trial results demonstrating their investigational microbiome-based therapeutic, SER-109, prevented recurrent C difficile infection (rCDI) in 88% of recipients.

“@sanjiv_chopra ➡️Microbiome is changing medicine & benefits of #FMT maybe beyond #Cdiff. Work in progress on alcoholism, autism, and others. ➡️AI will shape how we practice. EKG can predict cirrhosis ➡️CRISPR will shape the future of the human race @DDWMeeting #DDW2022”

Investigators sought information on how the infection is treated in outpatient clinics

“I'll be hosting this event next week - all my fellow #FMT nerds out there, please join me and @nadiamorim 💩🤓 #ECRchat @microbiome_net”

•Randomized, placebo-controlled trial•Standardized anaerobic feces storage •High alpha-diversity donors•Active UC frequently biologic-experienced recipients.•Study stopped early for futility #DDW2022— Kira Newman, MD, PhD (@KiraNewmanMDPhD) May 22, 2022

The Investor Relations website contains information about Seres Therapeutics's business for stockholders, potential investors, and financial analysts.

Kevin Litcofsky showed some very interesting data on how the SER-109 increases butyrate, valerate and hexaonate in #Cdiff patients which may contribute to prevention of recurrence #DDW2022 #SCFA #microbes pic.twitter.com/mc7hGS0wLB— Mindy Engevik (@MicroMindy) May 21, 2022

Thomas Louie is showing beautiful work using 8 bacterial strains to prevent the recurrence of #Cdiff #DDW2022 #microbes pic.twitter.com/NOt5GtrsVI— Mindy Engevik (@MicroMindy) May 21, 2022

SER-109 for Recurrent Clostridioides difficile Infection. Reply

The symptoms of Clostridioides difficile infection (CDI) are largely attributed to two C. difficile toxins, TcdA and TcdB. Significant efforts have been devoted to developing vaccines targeting both toxins through parenteral immunization routes. Recently, we generated a novel chimeric protein …

Correspondence from The New England Journal of Medicine — SER-109 for Recurrent Clostridioides difficile Infection

SER-109 for Recurrent Clostridioides difficile Infection

Clostridioides difficile infection is one of the leading causes of antibiotic-associated infectious diarrhea, and is associated with increased incidence and severity worldwide. While antibiotics have traditionally been used for prophylaxis and treatment of C. difficile infection, elevated antibiotic …

Rising incidences and mortalities have drawn attention to Clostridioides difficile infections (CDIs) in recent years. The main virulence factors of this bacterium are the exotoxins TcdA and TcdB, which glucosylate Rho-GTPases and thereby inhibit Rho/actin-mediated processes in cells. This res …

Destiny Pharma plc ("Destiny Pharma" or "the Company") World leading C. difficile scientists to present landmark data on the ability of NTCD-M3 to colonise the gut after antibiotic administration Brighton, United Kingdom – 12 May 2022 – Destiny Pharma (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that

GuruFocus Article or News written by Business Wire and the topic is about:

A novel antibiotic therapy for Clostridioides difficile infection, currently dubbed CRS3123, has demonstrated narrower selectivity and reduced bacterial derangement in the gut compared with other antibiotics.

Researchers have found that viruses called 'bacteriophages' are able to destroy the problematic Clostridium difficile bacterium and could lead to new treatment methods.

Exercise reduces inflammation, fatigue, and aids overall health. Additionally, physical fitness has been associated with desirable changes in the community composition of the athlete gut microbiome, with health-associated taxa being shown to be increased in active individuals. Here, using a combinat …

Clostridioides difficile (C. difficile) infection is associated with high morbidity and mortality. This study aimed to evaluate the protective effect of Lactiplantibacillus plantarum E51 (L. plantarum E51) on C. difficile infection using the Caco-2 monolayer in vitro model. Caco-2 cells were infecte …

The U.S. Food and Drug Administration (FDA) has removed the clinical hold on Finch Therapeutics Group (NASDAQ: FNCH) investigational new drug (IND) application for CP101 in  the prevention of recurrent C. difficile infection (CDI).

Adiso Therapeutics, Inc., a clinical-stage biotechnology company committed to creating medicines that treat inflammatory diseases and improve the lives of patients and their families, today announced the completion of patient enrollment in the Phase 1b clinical study evaluating ADS024, an orally delivered single strain live biotherapeutic product (SS-LBP), for the prevention of C. difficile infection (CDI) recurrence.

Adjuvant chemotherapy and colorectal anastomosis leakage increase risk of Clostridium difficile infection. Patients with Clostridium difficile infection also ha

Finch Therapeutics has slashed its headcount by 20% in order to free funds to focus its resources on its programs in recurrent C. difficile infection and autism spectrum disorder

Lumen Bioscience today announced clinical development progress for LMN-201, an investigational orally delivered cocktail to treat and prevent C. difficile infection (CDI).

SOMERVILLE, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics” or “Company”) (Nasdaq: FNCH), a...